Published in J Clin Endocrinol Metab on September 01, 1981
The dopamine D2 receptor: two molecular forms generated by alternative splicing. EMBO J (1989) 1.79
Prolactinomas. Br Med J (Clin Res Ed) (1985) 1.32
Failure of bromocriptine to maintain reduction in size of a macroprolactinoma. Br Med J (Clin Res Ed) (1983) 1.14
Prolactinoma. West J Med (1983) 0.79
The 'Alice in Wonderland' experience. Ergot alkaloid therapy for prolactin-secreting pituitary tumors. West J Med (1983) 0.75
Influence of cimetidine and bromocriptine on prolactin levels in rat fertility. Int J Physiol Pathophysiol Pharmacol (2008) 0.75
Morphologic effects of bromocriptine on spontaneously occurring pituitary prolactin-cell hyperplasia in old Long-Evans rats. Am J Pathol (1986) 0.75
Pituitary microadenomas: diagnostic and therapeutic trends. J Natl Med Assoc (1984) 0.75
Aminoglycoside toxicity--a survey of retinal specialists. Implications for ocular use. Arch Ophthalmol (1991) 3.09
Consensus statement on the diagnosis and treatment of children with idiopathic short stature: a summary of the Growth Hormone Research Society, the Lawson Wilkins Pediatric Endocrine Society, and the European Society for Paediatric Endocrinology Workshop. J Clin Endocrinol Metab (2008) 2.74
Inhibition of gastrin and gastric-acid secretion by growth-hormone release-inhibiting hormone. Lancet (1974) 2.65
Long-term treatment of acromegaly with bromocriptine. Br Med J (1977) 2.18
Treatment of acromegaly with the growth hormone-receptor antagonist pegvisomant. N Engl J Med (2000) 2.16
Long-term treatment of acromegaly with pegvisomant, a growth hormone receptor antagonist. Lancet (2001) 2.08
Dopamine is an important neurotransmitter in the autonomic nervous system. Lancet (1975) 1.99
Long-term treatment of galactorrhoea and hypogonadism with bromocriptine. Br Med J (1974) 1.98
Subretinal fluid stimulation of retinal pigment epithelial cell migration and proliferation is dependent on certain features of the detachment or its treatment. Arch Ophthalmol (1989) 1.98
Validity of methods of body composition assessment in young and older men and women. J Appl Physiol (1985) (1999) 1.82
Phase I trial of a melanoma vaccine with gp100(280-288) peptide and tetanus helper peptide in adjuvant: immunologic and clinical outcomes. Clin Cancer Res (2001) 1.79
The use of anthropometric and dual-energy X-ray absorptiometry (DXA) measures to estimate total abdominal and abdominal visceral fat in men and women. Obes Res (1999) 1.70
Bromocriptine treatment of acromegaly. Br Med J (1975) 1.70
Somatotroph hyperplasia. Successful treatment of acromegaly by removal of a pancreatic islet tumor secreting a growth hormone-releasing factor. J Clin Invest (1982) 1.60
Effects of sex and age on the 24-hour profile of growth hormone secretion in man: importance of endogenous estradiol concentrations. J Clin Endocrinol Metab (1987) 1.58
Neuroendocrine responses to a novel growth hormone secretagogue, L-692,429, in healthy older subjects. J Clin Endocrinol Metab (1994) 1.55
Repair of coronary artery perforation after rotastenting by implantation of the JoStent covered stent. Cathet Cardiovasc Diagn (1998) 1.50
Clinical risk factors for proliferative vitreoretinopathy. Arch Ophthalmol (1989) 1.49
Bromocriptine treatment of female infertility: report of 13 pregnancies. Br Med J (1975) 1.49
Letter: Metaclopramide and prolactin. Br Med J (1974) 1.48
Identification of novel rhodopsin mutations responsible for retinitis pigmentosa: implications for the structure and function of rhodopsin. Am J Hum Genet (1993) 1.45
Spatial contrast sensitivity is reduced in bilateral Parkinson's disease. Neurology (1991) 1.44
Induction of urinary tract infection by intraurethral inoculation with Escherichia coli: refining the murine model. J Infect Dis (1995) 1.43
Syndrome of anosmia with hypogonadotropic hypogonadism (Kallmann syndrome): clinical and laboratory studies in 23 cases. Am J Med (1982) 1.43
Pyridostigmine treatment selectively amplifies the mass of GH secreted per burst without altering GH burst frequency, half-life, basal GH secretion or the orderliness of GH release. Eur J Endocrinol (1997) 1.43
A longitudinal assessment of hormonal and physical alterations during normal puberty in boys. V. Rising leptin levels may signal the onset of puberty. J Clin Endocrinol Metab (1997) 1.42
Enhanced basal and disorderly growth hormone secretion distinguish acromegalic from normal pulsatile growth hormone release. J Clin Invest (1994) 1.42
Effects of a 7-day treatment with a novel, orally active, growth hormone (GH) secretagogue, MK-677, on 24-hour GH profiles, insulin-like growth factor I, and adrenocortical function in normal young men. J Clin Endocrinol Metab (1996) 1.40
Ciliary body adenoma in a 10-year-old girl who had a rhabdomyosarcoma. Arch Ophthalmol (1992) 1.37
Fasting enhances growth hormone secretion and amplifies the complex rhythms of growth hormone secretion in man. J Clin Invest (1988) 1.36
Impaired growth hormone responses to growth hormone-releasing factor in obesity. A pituitary defect reversed with weight reduction. N Engl J Med (1984) 1.35
Metabolic clearance of biologically active luteinizing hormone in man. J Clin Invest (1986) 1.33
Contemporary aspects of discrete peak-detection algorithms. I. The paradigm of the luteinizing hormone pulse signal in men. Endocr Rev (1988) 1.33
Multifocal osteosarcoma: a case report with review of the literature. Cancer (1979) 1.32
Stimulation of the growth hormone (GH)-insulin-like growth factor I axis by daily oral administration of a GH secretogogue (MK-677) in healthy elderly subjects. J Clin Endocrinol Metab (1996) 1.31
Molecular cloning and expression of a human anterior pituitary receptor for growth hormone-releasing hormone. Mol Endocrinol (1993) 1.27
Ultrastructural and electron-immunocytochemical characterization of cells in epiretinal membranes. Invest Ophthalmol Vis Sci (1990) 1.26
Idiopathic short stature: definition, epidemiology, and diagnostic evaluation. Growth Horm IGF Res (2008) 1.26
Somatostatin is contained in and released from cholinergic nerves in the heart of the toad Bufo marinus. Neuroscience (1982) 1.26
Half-time of endogenous growth hormone (GH) disappearance in normal man after stimulation of GH secretion by GH-releasing hormone and suppression with somatostatin. J Clin Endocrinol Metab (1989) 1.26
Growth hormone release inhibiting hormone in acromegaly. Br Med J (1974) 1.24
Adrenomedullary dysplasia and hypofunction in patients with classic 21-hydroxylase deficiency. N Engl J Med (2000) 1.24
Augmentation of growth hormone secretion during puberty: evidence for a pulse amplitude-modulated phenomenon. J Clin Endocrinol Metab (1987) 1.23
The frustration of state medicine 1880-1899. Med Hist (1967) 1.23
Human pancreatic growth-hormone-releasing factor selectively stimulates growth-hormone secretion in man. Lancet (1983) 1.23
Cryotherapy causes extensive breakdown of the blood-retinal barrier. A comparison with argon laser photocoagulation. Arch Ophthalmol (1985) 1.21
Vitrectomy techniques in the management of selected penetrating ocular injuries. Ophthalmology (1978) 1.21
Hormone pulsatility discrimination via coarse and short time sampling. Am J Physiol (1999) 1.20
Surgical complications of pars plana vitreous surgery. Ophthalmology (1978) 1.19
Pubertal alterations in growth and body composition. VI. Pubertal insulin resistance: relation to adiposity, body fat distribution and hormone release. Int J Obes Relat Metab Disord (2002) 1.19
Macular infarction after endophthalmitis treated with vitrectomy and intravitreal gentamicin. Arch Ophthalmol (1986) 1.17
Serum insulin-like growth factors I and II concentrations and growth hormone and insulin responses to arginine infusion in children with protein-energy malnutrition before and after nutritional rehabilitation. Pediatr Res (1986) 1.17
Adenovirus type 8 epidemic keratoconjunctivitis in an eye clinic: risk factors and control. J Infect Dis (1993) 1.17
Growth hormone and erythropoietin differentially activate DNA-binding proteins by tyrosine phosphorylation. Mol Cell Biol (1994) 1.16
Bilateral Horner's syndrome secondary to multinodular goiter. Ann Intern Med (1986) 1.15
Drugs five years later. Bromocriptine. Ann Intern Med (1984) 1.15
Relationship between growth hormone (GH) status, serum leptin and body composition in healthy and GH deficient elderly subjects. Clin Endocrinol (Oxf) (1997) 1.14
Alterations in growth and body composition during puberty. IV. Energy intake estimated by the youth-adolescent food-frequency questionnaire: validation by the doubly labeled water method. Am J Clin Nutr (2000) 1.12
Active transport of L-dopa in the intestine. Nature (1973) 1.12
An unusual presentation of McCune-Albright syndrome confirmed by an activating mutation of the Gs alpha-subunit from a bone lesion. J Clin Endocrinol Metab (1994) 1.12
Altered neuroendocrine regulation of gonadotropin secretion in women distance runners. J Clin Endocrinol Metab (1985) 1.11
Double pituitary lesions in three patients with Cushing's disease. Pituitary (2000) 1.10
Relationship between age, percentage body fat, fitness, and 24-hour growth hormone release in healthy young adults: effects of gender. J Clin Endocrinol Metab (1994) 1.10
Human prolactin-producing adenomas and bromocriptine: a histological, immunocytochemical, ultrastructural, and morphometric study. J Clin Endocrinol Metab (1982) 1.09
Physiology of growth and development. Its relationship to performance in the young athlete. Clin Sports Med (1995) 1.09
Pubertal alterations in growth and body composition. V. Energy expenditure, adiposity, and fat distribution. Am J Physiol Endocrinol Metab (2000) 1.08
Plasma prolactin concentrations and psychopathology in chronic schizophrenia. Arch Gen Psychiatry (1982) 1.08
The effects of dopamine, bromocriptine, lergotrile and metoclopramide on prolactin release from continuously perfused columns of isolated rat pituitary cells. Clin Endocrinol (Oxf) (1979) 1.08
Reduction of pituitary-tumour size in patients with prolactinomas and acromegaly treated with bromocriptine with or without radiotherapy. Lancet (1979) 1.08
X-chromosone-linked juvenile retinoschisis with hemorrhagic retinal cyst. Am J Ophthalmol (1977) 1.08
Abdominal visceral fat and fasting insulin are important predictors of 24-hour GH release independent of age, gender, and other physiological factors. J Clin Endocrinol Metab (2001) 1.08
Clinical and pathological effects of bromocriptine on prolactin-secreting and other pituitary tumors. J Neurosurg (1984) 1.07
Spontaneous oscillations of intracellular calcium and growth hormone secretion. J Biol Chem (1988) 1.07
Growth hormone stimulation testing in both short and normal statured children: use of an immunofunctional assay. Pediatr Res (2000) 1.07
Treatment of murine cytomegalovirus infections in severe combined immunodeficient mice with ganciclovir, (S)-1-[3-hydroxy-2-(phosphonylmethoxy)propyl]cytosine, interferon, and bropirimine. Antimicrob Agents Chemother (1992) 1.07
Letter: Antiemetics, prolactin, and breast cancer. Br Med J (1974) 1.07
Regulation of prolactin secretion at the level of the lactotroph. Physiol Rev (1990) 1.06
Temporal structure of in vivo growth hormone secretory events in humans. Am J Physiol (1991) 1.06
Contemporary aspects of discrete peak-detection algorithms. II. The paradigm of the luteinizing hormone pulse signal in women. Endocr Rev (1992) 1.06
Exercise training at and above the lactate threshold in previously untrained women. Int J Sports Med (1992) 1.06
Bromocriptine as primary therapy for prolactin-secreting macroadenomas: results of a prospective multicenter study. J Clin Endocrinol Metab (1985) 1.06
Sex steroids, growth hormone, insulin-like growth factor-1: neuroendocrine and metabolic regulation in puberty. Horm Res (1996) 1.05
11-cis retinol dehydrogenase mutations as a major cause of the congenital night-blindness disorder known as fundus albipunctatus. Mol Vis (1999) 1.05
A quantitative estimation of growth hormone secretion in normal man: reproducibility and relation to sleep and time of day. J Clin Endocrinol Metab (1992) 1.05
Augmented growth hormone (GH) secretory burst frequency and amplitude mediate enhanced GH secretion during a two-day fast in normal men. J Clin Endocrinol Metab (1992) 1.05
Alterations in body composition and fat distribution in growth hormone-deficient prepubertal children during growth hormone therapy. Metabolism (2001) 1.04
Both oral and transdermal estrogen increase growth hormone release in postmenopausal women--a clinical research center study. J Clin Endocrinol Metab (1996) 1.03
The influence of anatomical boundaries, age, and sex on the assessment of abdominal visceral fat. Obes Res (1997) 1.03
Letter: Digital vasospasm with bromocriptine. Lancet (1976) 1.03
Dopaminergic inhibition of metoclopramide-induced aldosterone secretion in man. Dissociation of responses to dopamine and bromocriptine. J Clin Invest (1980) 1.03
Ectopic secretion of corticotropin-releasing factor as a cause of Cushing's syndrome. A clinical, morphologic, and biochemical study. N Engl J Med (1984) 1.03
Estimation of daily cortisol production and clearance rates in normal pubertal males by deconvolution analysis. J Clin Endocrinol Metab (1993) 1.02
Growth hormone-releasing factor (GRF) regulates expression of its own receptor. Endocrinology (1996) 1.02
Pertussis toxin treatment attenuates some effects of insulin in BC3H-1 murine myocytes. J Biol Chem (1988) 1.02
Tetrabenazine has properties of a dopamine receptor antagonist. Ann Neurol (1982) 1.02